Physician profile
Lee Daniel Matlock
NPI 1467990820
$14,715.98
in general payments reported to CMS, 2019-2025
35 companies · $3,642 in 2025
The $3,642 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $2,378 · 2023: $4,008 · 2024: $4,216 · 2025: $3,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,651.07 |
| Education | $214.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,163.72 | 2022-2025 | |
| Amgen INC. | $2,469.74 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Astrazeneca Pharmaceuticals LP | $1,508.40 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,246.90 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $867.21 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $754.53 | 2022-2025 | |
| Pfizer INC. | $690.52 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $587.44 | 2022-2025 | Acthar |
| Lilly USA, LLC | $500.20 | 2022-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.63 | 2022-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $381.77 | 2022-2025 | Benlysta |
| Horizon Therapeutics Plc | $367.64 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $290.05 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $255.26 | 2022-2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $189.57 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $172.49 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $150.48 | 2023-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $81.00 | 2023 | Opsumit |
| Sobi, INC | $71.78 | 2022 | |
| Sandoz INC. | $71.64 | 2024-2025 | Hyrimoz |
| Novo Nordisk INC | $69.40 | 2021-2022 | |
| Genzyme Corporation | $58.13 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $57.22 | 2021-2022 | |
| Genentech USA, INC. | $51.35 | 2024-2025 | Actemra, Gazyva |
| Bayer Healthcare Pharmaceuticals INC. | $45.20 | 2021 | |
| Azurity Pharmaceuticals, INC. | $31.84 | 2023 | Horizant |
| Alexion Pharmaceuticals, INC. | $23.19 | 2021 | |
| Vifor Pharma, INC. | $22.37 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.01 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.69 | 2023 | Onpattro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.68 | 2022 | |
| Organon LLC | $15.94 | 2023 | Hadlima |
| Arbor Pharmaceuticals, INC. | $13.20 | 2022 | |
| Tersera Therapeutics LLC | $12.93 | 2023 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Matlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.